Co-treatment of Bcr-AbI positive cells with imatinib mesylate and histone deacetylase inhibitor.

被引：0
|
作者：
Kawano, T [1 ]
Yamada, JH [1 ]
Yamada, H [1 ]
机构：
[1] Jikei Univ, Inst DNA Med, Tokyo, Japan
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6264S / 6264S
页数：1
相关论文
共 50 条
  • [21] Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors
    Radujkovic, Aleksandar
    Topaly, Julian
    Fruehauf, Stefan
    Zeller, W. Jens
    ANTICANCER RESEARCH, 2006, 26 (3A) : 2169 - 2177
  • [22] Bim-EL, is sensitive to proteasome degradation and contributes to inducing apoptosis after in vitro imatinib mesylate treatment of BCR-ABL positive cells.
    Belloc, F
    Boyer, C
    Lacombe, F
    Praloran, V
    Mahon, FX
    BLOOD, 2004, 104 (11) : 253B - 253B
  • [23] Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells
    Cheong, JW
    Chong, SY
    Kim, JY
    Eom, JI
    Jeung, HK
    Maeng, HY
    Lee, ST
    Min, YH
    CLINICAL CANCER RESEARCH, 2003, 9 (13) : 5018 - 5027
  • [24] The Efficacy of Histone Deacetylase Inhibitor, Vorinostat against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Monotherapy and in Combination with Dasatinib
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Kimura, Shinya
    Maekawa, Taira
    Ohyashiki, Kazuma
    Ashihara, Eishi
    BLOOD, 2008, 112 (11) : 1096 - 1096
  • [25] Stimulation of glucose uptake in muscle cells by prolonged treatment with scriptide, a histone deacetylase inhibitor
    Takigawa-Imamura, H
    Sekine, T
    Murata, M
    Takayama, K
    Nakazawa, K
    Nakagawa, J
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2003, 67 (07) : 1499 - 1506
  • [26] Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells
    Kamyabi, Rohollah
    Jahandideh, Alireza
    Panahi, Negar
    Muhammadnejad, Samad
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2023, 26 (03) : 359 - 366
  • [27] The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate
    Gatto, S
    Scappini, B
    Pham, L
    Onida, F
    Milella, M
    Ball, G
    Ricci, C
    Divoky, V
    Verstovsek, S
    Kantarjian, HM
    Keating, MJ
    Cortes, JE
    Beran, M
    HAEMATOLOGICA, 2003, 88 (08) : 853 - 863
  • [28] Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer
    Venkannagari, Sreedhar
    Fiskus, Warren
    Peth, Karissa
    Atadja, Peter
    Hidalgo, Manuel
    Maitra, Anirban
    Bhalla, Kapil N.
    ONCOTARGET, 2012, 3 (11) : 1416 - 1427
  • [29] Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
    Seiichi Okabe
    Tetsuzo Tauchi
    Yuko Tanaka
    Shinya Kimura
    Taira Maekawa
    Kazuma Ohyashiki
    Cancer Cell International, 13
  • [30] Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Tanaka, Yuko
    Kimura, Shinya
    Maekawa, Taira
    Ohyashiki, Kazuma
    CANCER CELL INTERNATIONAL, 2013, 13
12345